Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction.
Anti-(+)-methamphetamine monoclonal antibodies (mAbs) have the potential to reduce the devastating behavioral and societal effects of the worldwide epidemic of (+)-methamphetamine (METH) addiction and transform the treatment paradigm for diseases of addiction. These novel, protein-based medications could play a vital role in helping patients to achieve sustainable abstinence from METH abuse by serving as an in vivo, around-the-clock sentry against a patient's vulnerability to relapse.
Gentry
W B
WB
Department of Anesthesiology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Rüedi-Bettschen
D
D
Owens
S M
SM
D019969:Amphetamine-Related Disorders / Q000276:immunology / Q000534:rehabilitation*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D018450:Disease Progression; D016503:Drug Delivery Systems; D006801:Humans; D008694:Methamphetamine / Q000009:adverse effects* / Q000276:immunology; D055502:Secondary Prevention
D000911:Antibodies, Monoclonal; D003692:Delayed-Action Preparations; D008694:Methamphetamine